title: Continuous glucose monitoring and insulin pump therapy for diabetes in pregnancy.
abstract: Continuous glucose monitoring (CGM) systems and continuous subcutaneous insulin infusion (CSII) systems, or insulin pumps, offer great promise for improved glycemic control during pregnancy. Combined, these two devices could potentially constitute an artificial pancreas, where real-time blood glucose readings are relayed to an insulin pump that uses a personalized algorithm to decide how much insulin is needed by the patient's body. However, the promise of these two systems have not yet been proven individually or in combination in controlled clinical trials to improve pregnancy outcomes. Such trials are urgently needed before the widespread use of these devices in pregnancy can be justified.
authors.affiliation: Obstetrix Medical Group, San Jose, CA, USA. andrewcombs@me.com
authors.forename: C Andrew
authors.initials: CA
authors.lastname: Combs
mesh_terms: D015190:Blood Glucose Self-Monitoring; D016640:Diabetes, Gestational / Q000097:blood / Q000188:drug therapy*; D005260:Female; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage* / Q000627:therapeutic use; D015918:Infusion Pumps, Implantable; D007328:Insulin / Q000008:administration & dosage* / Q000627:therapeutic use; D007332:Insulin Infusion Systems; D011247:Pregnancy; D011254:Pregnancy in Diabetics / Q000097:blood / Q000188:drug therapy*; D011295:Prenatal Care; D016896:Treatment Outcome
chemical_list: D007004:Hypoglycemic Agents; D007328:Insulin